Two galaxies seen in a 'joust' preceding a cosmic mega-merger
WASHINGTON (Reuters) - Astronomers have observed two distant galaxies - both possessing roughly as many stars as our Milky Way - careening toward each other before their inevitable merger at a time when the universe was about a fifth its current age, a scene resembling two knights charging in a joust.
The galaxies, observed using two Chile-based telescopes, were seen as they existed about 11.4 billion years ago, approximately 2.4 billion years after the Big Bang event that initiated the universe.
At the heart of one of the galaxies resides a quasar, a highly luminous object powered by gas and other material falling into a supermassive black hole. The intense radiation across the electromagnetic spectrum unleashed by the quasar is seen disrupting clouds of gas and dust, known as molecular clouds, in the other galaxy.
It is molecular clouds that give rise to stars. But the effects of the quasar's radiation turned the clouds in the affected region into "only tiny dense cloudlets that are too small to form stars," said astrophysicist Sergei Balashev of the Ioffe Institute in Saint Petersburg, Russia, co-lead author of the study published on Wednesday in the journal Nature.
This is the first time such a phenomenon has been observed, Balashev said.
Stars form by the slow contraction under gravity of these clouds, with small centers taking shape that heat up and become new stars. But the galaxy affected by the quasar's radiation was left with fewer regions that could serve as such stellar nurseries, undermining its star formation rate.
The interaction between the two galaxies reminded the researchers of a medieval joust.
"Much like jousting knights charging toward one another, these galaxies are rapidly approaching. One of them - the quasar host - emits a powerful beam of radiation that pierces the companion galaxy, like a lance. This radiation 'wounds' its 'opponent' as it disrupts the gas," said astronomer and co-lead author Pasquier Noterdaeme of the Paris Institute of Astrophysics in France.
Supermassive black holes are found at the heart of many galaxies, including the Milky Way. The researchers estimated the mass of the one that serves as the engine of the quasar studied in this research at about 200 million times that of our sun.
The intense gravitational strength of the supermassive black hole pulls gas and other material toward it. As this stuff spirals inward at high speed, it heats up due to friction, forming a disk that emits extremely powerful radiation in two opposite directions, called biconical beams.
The ultraviolet light from one of these beams is what played havoc with the gas in the companion galaxy.
This supermassive black hole is much more massive than the one at the center of the Milky Way - called Sagittarius A*, or Sgr A* - which possesses roughly 4 million times the mass of the sun and is located about 26,000 light-years from Earth. A light-year is the distance light travels in a year, 5.9 trillion miles (9.5 trillion km).
The researchers used the Atacama Large Millimeter/submillimeter Array, or ALMA, to characterize the two galaxies and used the European Southern Observatory's Very Large Telescope, or VLT, to probe the quasar as well as the gas in the companion galaxy.
The configuration of the galaxies as viewed from the perspective of Earth enabled the researchers to observe the radiation from the quasar passing directly through the companion galaxy.
Most galactic mergers that have been observed by astronomers occurred later in the history of the universe.
"Galaxies are typically found in groups, and gravitational interactions naturally lead to mergers over cosmic time," Noterdaeme said. "In line with current understanding, these two galaxies will eventually coalesce into a single larger galaxy. The quasar will fade as it exhausts the available fuel."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
a few seconds ago
- Boston Globe
Biogen sees potential in combining Alzheimer's and obesity drugs
Advertisement Biogen's looking to the growth of its Alzheimer's drug Leqembi to offset the decline of its multiple sclerosis franchise, which is facing competition from cheaper generic drugs. Biogen's new Alzheimer's drug is already facing competition from Eli Lilly & Co.'s Alzheimer's drug, which was approved in the US last year and has since captured around 30 percent of the market, according to analysts. Other companies are also circling. Novo is carrying out clinical trials to assess whether the main ingredient in diabetes drug Ozempic and weight-loss shot Wegovy might help people with early Alzheimer's disease. Research suggests that the weight-loss drug could slow Alzheimer's progression by impacting inflammation and vascular health. Results of Novo's late-stage trial are expected later this year. Advertisement Viehbacher noted that being overweight is a risk factor for Alzheimer's. He cautioned the Novo study 'is a fairly risky proposition,' adding that 'most of the experts we're talking to are not convinced that it will work.' 'It's logical if you have a weight-loss drug that you can see some benefit, but it's actually pretty hard to move the needle on the cognitive side,' Viehbacher added. Alzheimer's drug development has been riddled with failures, even when drugs looked promising in early studies. Leqembi is a partnership between Cambridge, Massachusetts-based Biogen and Japanese drugmaker Eisai Co. Biogen makes the active ingredient for Leqembi in Switzerland. The company then ships it to North Carolina, where it gets made into a product. President Donald Trump recently put a 39 percent tariff on imports from Switzerland. It's unclear whether this would impact Biogen's drug. Still, Viehbacher said the company has the ability to start producing the substance used to make Leqembi in North Carolina for the US market, while continuing to make it in Switzerland for outside the US. He said the company always intended to use its North Carolina facilities to make Leqembi and the potential move was not a direct response to Trump's tariff threats. Last month, Biogen announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park.
Scientific American
31 minutes ago
- Scientific American
Trump Order Gives Political Appointees Vast Powers over Research Grants
US President Donald Trump issued an expansive executive order (EO) yesterday that would centralize power and upend the process that the US government has used for decades to award research grants. If implemented, political appointees — not career civil servants, including scientists — would have control over grants, from initial funding calls to final review. This is the Trump administration's latest move to assert control over US science. The EO, titled 'Improving Oversight of Federal Grantmaking', orders each US agency head to designate an appointee to develop a grant-review process that will 'advance the President's policy priorities'. Those processes must not fund grants that advance 'anti-American values' and instead prioritize funding for institutions committed to achieving Trump's plan for 'gold-standard science'. (That plan, issued in May, calls for the US government to promote 'transparent, rigorous, and impactful' science, but has been criticized for its potential to increase political interference in research.) Impacts might be felt immediately: the latest order directs US agencies, such as the National Institutes of Health (NIH), to halt new funding opportunities, which are calls for researchers to submit applications for grants on certain topics. They will be paused until agencies put their new review processes in place. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. Trump's EO comes after the US Senate — which, along with the House, ultimately controls US government spending — has, in recent weeks, mostly rejected his proposals to slash the federal budget for science, totalling nearly US$200 billion annually. The White House did not respond to questions from Nature about the EO. Negative reaction Trump, a Republican, has previously used EOs, which can direct government agencies but cannot alter existing laws, to effect policy change. In January, on his first day in office, he signed a slew of EOs with wide-ranging effects, from pulling the United States out of the Paris climate agreement to cutting the federal workforce, which had included nearly 300,000 scientists before he took office. Scientists and policy specialists have lambasted the latest EO on social media. 'This is a shocking executive order that undermines the very idea of open inquiry,' Casey Dreier, director of space policy for the Planetary Society, an advocacy group in Pasadena, California, posted to Bluesky. Also on Bluesky, Jeremy Berg, a former director of the NIH's National Institute of General Medical Sciences, called it a 'power grab'. Speaking to Nature, he said: 'That power is something that has not been exercised at all in the past by political appointees.' In a statement, Zoe Lofgren, a Democratic member of the US House of Representatives from California, called the EO 'obscene'. It could lead to political appointees 'standing between you and a cutting-edge cancer-curing clinical trial', she said. The EO justifies the changes to the grant-awarding process by casting doubts on past choices: it accuses the US National Science Foundation (NSF) of awarding grants to educators with anti-American ideologies and to projects on diversity, equity and inclusion, which are disfavoured by the Trump team. It also points to senior researchers at Harvard University in Cambridge, Massachusetts, and Stanford University in California who have resigned over accusations of data falsification. To 'strengthen oversight' of grants, the EO imposes several restrictions, including prohibiting grants that promote 'illegal immigration' and prohibiting grant recipients from promoting 'racial preferences' in their work or denying that sex is binary. In some cases, the restrictions seem to contradict Congressional mandates. For instance, the NSF has, for decades, been required by law to broaden participation in science of people from under-represented groups — an action that takes race into consideration. In addition to these broader restrictions, the EO directs grant approvals to prioritize certain research institutions, such as those that have 'demonstrated success' in implementing the gold-standard science plan and those with lower 'indirect costs'. As part of its campaign to downsize government spending and reduce the power of elite US universities, the Trump administration has repeatedly tried to cap these costs — used to pay for laboratory electricity and administrative staff, for instance. It has proposed a flat 15% rate for grants awarded by agencies such as the NSF and the US Department of Energy, but federal courts have so far blocked such policies. Some institutions with the highest indirect-cost rates are children's hospitals, Berg told Nature. 'Does that mean they're just not going to prioritize research at children's hospitals?' he asks. Out for review At the heart of the grant-awarding process is peer review. Project proposals have typically had to pass watchful panels of independent scientists who scored and approved funding. 'Nothing in this order shall be construed to discourage or prevent the use of peer review methods,' the EO notes, 'provided that peer review recommendations remain advisory' to the senior appointees. The EO worries many researchers, including Doug Natelson, a physicist at Rice University in Houston, Texas. 'This looks like an explicit attempt to destroy peer review for federal science grants,' he says. Programme officers at agencies, who have been stewards of the grant-review process, are similarly alarmed. 'The executive order is diminishing the role of programme officers and their autonomy to make judgments about the quality of the science,' says an NSF employee who requested anonymity because they are not authorized to speak with the press. 'That's disheartening, to say the least.'
Geek Wire
2 hours ago
- Geek Wire
Ai2 unveils MolmoAct: Open-source robotics system reasons in 3D and adjusts on the fly
Jiafei Duan, Ai2 researcher, shows MolmoAct controlling a robotic arm. (GeekWire Photo / Todd Bishop) The Allen Institute for AI released a new AI robotics system that uses novel approaches to help robots navigate messy real-world environments, while making all of the model's code, data, and training methods publicly available under open-source principles. The system, called MolmoAct, converts 2D images into 3D visualizations, previews its movements before acting, and lets human operators adjust those actions in real time. It differs from existing robotics models that often work as opaque black boxes, trained on proprietary datasets. Ai2 expects the system to be used by robotics researchers, companies, and developers as a foundation for building robots that can operate in unstructured environments such as homes, warehouses, and disaster response scenes. In demos last week at Ai2's new headquarters north of Seattle's Lake Union, researchers showed MolmoAct interpreting natural language commands to direct a robotic arm to pick up household objects, such as cups and plush toys, and move them to specific locations. Researchers described it as part of AI2's broader efforts to create a comprehensive set of open-source AI tools and technologies. The Seattle-based research institute was founded in 2014 by the late Microsoft co-founder Paul Allen, and is funded in part by his estate. Ai2's flagship OLMo large language model is a fully transparent alternative to proprietary systems, with openly available training data, code, and model weights, designed to support research and public accountability in AI development. The institute's projects are moving in 'one big direction' — toward a unified AI model 'that can do reasoning and language, that can understand images, videos, that can control a robot, and that can make sense of space and actions,' said Ranjay Krishna, Ai2's research lead for computer vision, and a University of Washington Allen School assistant professor. MolmoAct builds on AI2's Molmo multimodal AI model — which can understand and describe images — by adding the ability to reason in 3D and direct robot actions.
